41. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Issue 4 (April 2015) Authors: Weber, Jeffrey S; D'Angelo, Sandra P; Minor, David; Hodi, F Stephen; Gutzmer, Ralf; Neyns, Bart; Hoeller, Christoph; Khushalani, Nikhil I; Miller, Wilson H; Lao, Christopher D; Linette, Gerald P; Thomas, Luc; Lorigan, Paul; Grossmann, Kenneth F; Hassel, Jessica C; Maio, Michele; Sznol, Mario; Asc... Journal: Lancet oncology Issue: Volume 16:Issue 4(2015:Apr.) Page Start: 375 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
42. No longer an untreatable disease: How targeted and immunotherapies have changed the management of melanoma patients. Issue 6 (15th August 2014) Authors: Girotti, Maria Romina; Saturno, Grazia; Lorigan, Paul; Marais, Richard Other Names: Peeper Daniel specialEditor. Journal: Molecular oncology Issue: Volume 8:Issue 6(2014:Sep.) Page Start: 1140 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
43. On the potential beneficial effects of indoor tanning: reply from the authors. (16th September 2022) Authors: Eden, Martin; Hainsworth, Rob; Gordon, Louisa G.; Epton, Tracy; Lorigan, Paul; Rhodes, Lesley E.; Marais, Richard; Green, Adele C.; Payne, Katherine Journal: British journal of dermatology Issue: Volume 187:Number 6(2022) Page Start: 1057 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
44. On the potential beneficial effects of indoor tanning: reply from the authors. (1st December 2022) Authors: Eden, Martin; Hainsworth, Rob; Gordon, Louisa G.; Epton, Tracy; Lorigan, Paul; Rhodes, Lesley E.; Marais, Richard; Green, Adele C.; Payne, Katherine Journal: British journal of dermatology Issue: Volume 187:Number 6(2022) Page Start: 1057 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
45. Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer. Issue 2 (May 2015) Authors: Howell, Matthew; Lee, Rebecca; Bowyer, Samantha; Fusi, Alberto; Lorigan, Paul Journal: Lung cancer Issue: Volume 88:Issue 2(2015:May) Page Start: 117 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
46. Patient and treatment characteristics of emergency presentations due to immune-mediated toxicities. (March 2022) Authors: Nahm, Sharon H.; Heywood, Richard; Callaghan, Sophia; Serra-Bellver, Patricio; Gupta, Avinash; Cooksley, Tim; Lorigan, Paul Journal: European journal of cancer Issue: Volume 164(2022) Page Start: 62 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
47. PD-L1 expression as a potential predictive biomarker. Issue 13 (October 2015) Authors: Fusi, Alberto; Festino, Lucia; Botti, Gerado; Masucci, Giuseppe; Melero, Ignacio; Lorigan, Paul; Ascierto, Paolo A Journal: Lancet oncology Issue: Volume 16:Issue 13(2015) Page Start: 1285 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
48. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Issue 10105 (21st October 2017) Authors: Schachter, Jacob; Ribas, Antoni; Long, Georgina V; Arance, Ana; Grob, Jean-Jacques; Mortier, Laurent; Daud, Adil; Carlino, Matteo S; McNeil, Catriona; Lotem, Michal; Larkin, James; Lorigan, Paul; Neyns, Bart; Blank, Christian; Petrella, Teresa M; Hamid, Omid; Zhou, Honghong; Ebbinghaus, Scot; Ibr... Journal: Lancet Issue: Volume 390:Issue 10105(2017) Page Start: 1853 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
49. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Issue 9 (September 2019) Authors: Robert, Caroline; Ribas, Antoni; Schachter, Jacob; Arance, Ana; Grob, Jean-Jacques; Mortier, Laurent; Daud, Adil; Carlino, Matteo S; McNeil, Catriona M; Lotem, Michal; Larkin, James M G; Lorigan, Paul; Neyns, Bart; Blank, Christian U; Petrella, Teresa M; Hamid, Omid; Su, Shu-Chih; Krepler, Clemen... Journal: Lancet oncology Issue: Volume 20:Issue 9(2019) Page Start: 1239 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
50. Potential pitfalls in diagnosis of immunotherapy-induced hypothalamic–pituitary–adrenal axis abnormalities: a clinical case. Issue 1 (26th July 2022) Authors: Bi, Yixi; Adam, Safwaan; Chatzimavridou, Viktoria; Lorigan, Paul; Huang, Yinglai Journal: Endocrine oncology Issue: Volume 2:Issue 1(2022) Page Start: K5 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗